Globus Medical (NYSE:GMED) Releases FY 2025 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 3.400-3.500 for the period, compared to the consensus earnings per share estimate of 3.420. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion. Globus Medical also updated its FY 2024 guidance to EPS.

Globus Medical Stock Up 3.5 %

Shares of GMED traded up $2.89 during trading on Wednesday, reaching $86.34. 1,473,717 shares of the company traded hands, compared to its average volume of 993,656. The stock has a 50-day simple moving average of $82.33 and a 200-day simple moving average of $74.86. The stock has a market cap of $11.76 billion, a PE ratio of 128.87, a price-to-earnings-growth ratio of 1.97 and a beta of 1.19. Globus Medical has a twelve month low of $49.33 and a twelve month high of $87.22.

Globus Medical (NYSE:GMED) last announced its earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.18. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The company had revenue of $625.71 million for the quarter, compared to analyst estimates of $604.69 million. During the same quarter in the previous year, the company earned $0.57 earnings per share. The firm’s quarterly revenue was up 63.1% compared to the same quarter last year. On average, equities research analysts predict that Globus Medical will post 2.97 EPS for the current year.

Analyst Upgrades and Downgrades

GMED has been the subject of a number of research analyst reports. Stifel Nicolaus raised their target price on Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Wells Fargo & Company raised their price objective on shares of Globus Medical from $88.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $83.00 to $100.00 in a research note on Monday, December 2nd. Roth Mkm raised their price target on shares of Globus Medical from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 17th. Finally, Royal Bank of Canada boosted their price target on shares of Globus Medical from $80.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $94.55.

Insider Transactions at Globus Medical

In related news, CEO Daniel T. Scavilla sold 60,000 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total value of $4,801,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Kelly Huller sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $81.01, for a total transaction of $405,050.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 97,500 shares of company stock valued at $7,674,950. 18.54% of the stock is currently owned by corporate insiders.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.